FDA Approves New Genetic Test For Breast Cancer Patients
The U.S. Food and Drug Administration has approved a test that helps in assessing the risk of tumor recurrence and long-term survival for patients with relatively high-risk breast cancer. The TOP2A FISH pharmDx is the first approved device to test for the TOP2A (topoisomerase 2 alpha) gene in cancer patients. The TOP2A gene plays a role in DNA replication.
More: continued here
Filed under: Breast Cancer on January 17th, 2008